KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Amneal Pharmaceuticals (AMRX) Capital Expenditures (2017 - 2026)

Amneal Pharmaceuticals has reported Capital Expenditures over the past 9 years, most recently at $21.8 million for Q4 2025.

For Q4 2025, Capital Expenditures rose 43.67% year-over-year to $21.8 million; the TTM value through Dec 2025 reached $70.1 million, up 34.93%, while the annual FY2025 figure was $70.1 million, 34.93% up from the prior year.
Capital Expenditures for Q4 2025 was $21.8 million at Amneal Pharmaceuticals, up from $12.3 million in the prior quarter.
Over five years, Capital Expenditures peaked at $22.8 million in Q2 2025 and troughed at $5.0 million in Q2 2022.
A 5-year average of $13.0 million and a median of $11.7 million in 2021 define the central range for Capital Expenditures.
Biggest five-year swings in Capital Expenditures: tumbled 40.75% in 2021 and later surged 137.73% in 2023.
Year by year, Capital Expenditures stood at $17.5 million in 2021, then tumbled by 34.47% to $11.5 million in 2022, then dropped by 13.96% to $9.9 million in 2023, then soared by 53.62% to $15.2 million in 2024, then skyrocketed by 43.67% to $21.8 million in 2025.
Business Quant data shows Capital Expenditures for AMRX at $21.8 million in Q4 2025, $12.3 million in Q3 2025, and $22.8 million in Q2 2025.